157 related articles for article (PubMed ID: 22555096)
21. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
22. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
23. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
24. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.
Sankaranarayanan R; Bhatla N; Gravitt PE; Basu P; Esmy PO; Ashrafunnessa KS; Ariyaratne Y; Shah A; Nene BM
Vaccine; 2008 Aug; 26 Suppl 12():M43-52. PubMed ID: 18945413
[TBL] [Abstract][Full Text] [Related]
26. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.
Accetta G; Biggeri A; Carreras G; Lippi G; Carozzi FM; Confortini M; Zappa M; Paci E
J Med Screen; 2010; 17(4):181-9. PubMed ID: 21258128
[TBL] [Abstract][Full Text] [Related]
27. The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.
Brown VL; Jane White KA
Math Biosci; 2011 Jun; 231(2):126-34. PubMed ID: 21377481
[TBL] [Abstract][Full Text] [Related]
28. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
29. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
30. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
[TBL] [Abstract][Full Text] [Related]
31. Global human papillomavirus vaccination: can it be cost-effective?
Crosbie EJ
BJOG; 2012 Jan; 119(2):125-8. PubMed ID: 22168760
[No Abstract] [Full Text] [Related]
32. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
33. Start early to prevent genital HPV infection-and cervical cancer.
Heavey E
Nursing; 2008 May; 38(5):62-3. PubMed ID: 18431214
[No Abstract] [Full Text] [Related]
34. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
[TBL] [Abstract][Full Text] [Related]
35. [Methodological aspects of clinical and economic impact of vaccine interventions and HTA. Focus on HPV vaccination].
Ricciardi W; Dirodi B; Bonanni P; Capri S; Castiglia P; Gabutti G; Gasparini R; Giorgi Rossi P; Grilli G; La Torre G
Ann Ig; 2011; 23(5):419-34. PubMed ID: 22403995
[TBL] [Abstract][Full Text] [Related]
36. The current and future role of screening in the era of HPV vaccination.
Myers E; Huh WK; Wright JD; Smith JS
Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
[TBL] [Abstract][Full Text] [Related]
37. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise.
Torvinen S; Nieminen P; Lehtinen M; Paavonen J; Demarteau N; Hahl J
J Med Econ; 2010; 13(2):284-94. PubMed ID: 20482244
[TBL] [Abstract][Full Text] [Related]
39. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
40. Challenges of implementing human papillomavirus (HPV) vaccination policy.
Raffle AE
BMJ; 2007 Aug; 335(7616):375-7. PubMed ID: 17717366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
